Back to News
Market Impact: 0.2
Annovis Bio Consensus Price Target Lowered by 16.67% to $10.71
Source: Nasdaq
Analyst EstimatesHealthcare & Biotech
The aggregate one-year analyst price target for Annovis Bio was cut 16.67% to $10.71 per share as of September 11, 2026, from $12.85 on August 25. The target reduction signals weaker analyst valuation expectations for the biotech company, though the article provides no underlying changes to earnings, clinical, or operating forecasts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly negative
Sentiment Score
-0.32
Ticker Sentiment
ANVS-0.40
More News
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Evercore ISI cuts Reddit stock rating on user growth concerns
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat